In conversation with... Peter De Cruz episode artwork

EPISODE · Nov 6, 2024 · 14 MIN

In conversation with... Peter De Cruz

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

NOW PLAYING

In conversation with... Peter De Cruz

0:00 14:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 14 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on November 6, 2024.

What is this episode about?

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!